Persica Pharmaceuticals

Persica Pharmaceuticals is a clinical-stage pharmaceutical company developing PP353, a unique intradiscal antibiotic formulation for the treatment of patients with chronic low back pain (CLBP). These patients are experiencing a debilitating and persistent condition that significantly impacts their quality of life, while existing treatments, including exercise, physical therapy, and even invasive surgery, are largely ineffective.